GlobeNewswire

Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

Share

 Company to Discontinue Current Nolasiban IVF Program

Geneva, Switzerland and Boston, MA – November 7, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that the Phase 3 clinical trial results from its European confirmatory study of nolasiban (IMPLANT 4) in women undergoing embryo transfer (ET) following in-vitro fertilization (IVF) did not meet the primary endpoint of an increase in ongoing pregnancy rate at 10 weeks, (39.1 % placebo vs 40.5 % nolasiban) (p = 0.745). Nolasiban was well tolerated. All subjects will continue to be followed up to delivery and infant development will be assessed up to 6 months.

IMPLANT4 is a randomized, double blind, placebo controlled clinical trial that included 807 patients from more than 40 fertility clinics across nine European countries. Women undergoing a Day 5 transfer of a single, fresh embryo were randomized to receive either a single 900 mg dose of nolasiban or placebo (1:1) 4 hours prior to ET.  The primary endpoint of the trial was ongoing pregnancy as determined by ultrasound at 10 weeks following ET. 

"We are extremely disappointed with these unexpected results, not in the least for the millions of women hoping to have a baby through IVF. I would like to acknowledge the excellent execution of the study by our employees, and to thank our investigators as well as the women who participated in our trials,” said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva. “Based on these results, we have decided to discontinue the current nolasiban IVF program and will explore potential repositioning of the product candidate. We remain more committed than ever to developing our innovative pipeline of late-stage products aimed at unmet needs in uterine fibroids, endometriosis and preterm labor and will focus our resources on these programs immediately.”

Conference Call

ObsEva will host a conference call and audio webcast today beginning at 8:00 a.m. Eastern Time/2:00 p.m. Central European Time to discuss IMPLANT 4 trial results and third quarter financial results.  Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers and referring to conference ID 9273485.  A live or archived webcast of the conference call can be accessed under the “Investors” section of ObsEva’s website www.obseva.com.

About Nolasiban

Nolasiban (previously known as OBE001), is an oral oxytocin receptor antagonist which was licensed from Merck KGaA, Darmstadt, Germany, in 2013. ObsEva retains worldwide, exclusive, commercial rights.

About linzagolix

Linzagolix (previously known as OBE2109) is a novel, orally administered GnRH receptor antagonist with a potentially best-in-class profile in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for linzagolix.

About OBE022

ObsEva is developing OBE022, a potential first-in-class, once daily, oral and selective prostaglandin F2alpha receptor antagonist for the treatment of preterm labor. OBE022 was licensed from Merck KGaA, Darmstadt, Germany, in 2015. ObsEva retains worldwide, exclusive, commercial rights.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com .

Cautionary Note Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include statements regarding the potential to reposition nolasiban. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development and related regulatory reviews and approvals, including the risk that the results of earlier clinical trials may not be predictive of the results of later-stage clinical trials, ObsEva’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2018, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.obseva.com . Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
cla@dynamicsgroup.ch
+41 22 308 6220 Office
+41 79 476 26 87 Mobile

Media Contact U.S.:
Marion Janic
RooneyPartners LLC
mjanic@rooneyco.com
+1 212 223 4047 Office
+1 646 537 5649 Mobile

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile

###

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Nordic American Tankers Limited (NYSE: NAT) AGM successfully concluded today. All recommendations of the NAT Board approved.20.11.2019 20:32:00 CETPress release

Bermuda November 20, 2019 Nordic American Tankers Limited (NYSE: NAT) (the “Company”) is pleased to announce that all of the proposals at its Annual General Meeting have been approved by its shareholders by well over the required margin. These proposals are: --appointment of six directors for a term of one year. The NAT board of directors is now composed of; - Herbjorn Hansson, Norway - Andreas Ove Ugland, Cayman Island - James Kelly, USA - David Workman, United Kingdom - Richard H.K. Vietor, USA - Alexander Hansson, Monaco --reduction of the Company’s share premium account to facilitate the payment of dividends. --appointment of KPMG AS as the Company’s independent auditor Herbjorn Hansson, the Company’s Chairman and Chief Executive Officer, stated: “We believe that the approval of all of the proposals at the Annual General Meeting are a recognition of the Company’s emphasis on good corporate governance.” CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Matters discussed in t

Leasinvest Real Estate SCA: 2019 Bond Private Placement20.11.2019 19:30:00 CETPress release

Bond private placement for an amount of EUR 100 million Leasinvest Real Estate SCA today successfully issued a 7-year private placement of bonds amounting to EUR 100 million, in denominations of EUR 100,000. The bonds offer a fixed annual coupon of 1.95% and have been placed with investors in Belgium, France and Luxembourg. BNP Paribas Fortis and Degroof Petercam were appointed as Global Coordinators of the transaction. BNP Paribas Fortis, Degroof Petercam and KBC acted as Joint Bookrunners of the transaction. The placement fits within Leasinvest Real Estate’s strategy to arrange financing sources best suited to carry out its investment strategy both through acquisitions and redevelopment of existing core assets. The proceeds will, amongst other things, serve to refinance the EUR 75 million public bond which matured on 9 October 2019 and will contribute to an increase of the average duration of the total debt of Leasinvest Real Estate and a diversification of its financing sources. MIC

IMCD expands Americas footprint by acquiring Colombian specialty distributor Unired Químicas20.11.2019 19:00:00 CETPress release

ROTTERDAM, The Netherlands (20 November 2019) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of specialty chemicals and food ingredients, today announced that it has acquired 100% of the outstanding shares of the Colombia-based ingredient distributor, Unired Químicas SAS (“Unired”). With an office in Bogota, Colombia, Unired distributes specialty chemicals and ingredients to the pharmaceutical, food and personal care markets. In 2018, Unired generated a revenue of USD 8 million and has approximately 15 employees. The company will be fully integrated with IMCD’s organisation in 2020. Please find attached the full press release. Attachment PRESS RELEASE_IMCD expands Americas footprint by acquiring Colombian specialty distributor Unired Químicas

Agfa-Gevaert: Publication of a transparency notification (Axxioon) – Regulated information20.11.2019 17:40:00 CETPress release

(Article 14 of the law of May 2, 2007 on the disclosure of significant shareholdings) Mortsel, Belgium – November 20, 2019 – 5.40 p.m. CET According to Agfa-Gevaert NV’s bylaws, the threshold as from which a shareholding needs to be disclosed, has been set at 3%, 5% and a multiple of 5%. In conformity with the Law of May 2, 2007 regarding the disclosure of significant shareholdings in listed companies, Agfa-Gevaert (Euronext: AGFB) discloses the following declaration: On November 19, 2019, Axxion S.A. has announced that as per November 15, 2019, it holds a stake in Agfa-Gevaert of 5,598,000 shares or 3.26% (denominator is 171,851,042), thus crossing the 3% threshold upwards. Notifications of important shareholdings to be made according to the Law of May 2, 2007 or Agfa-Gevaert NV’s bylaws, should be sent to viviane.dictus@agfa.com. About Agfa The Agfa-Gevaert Group develops, manufactures and distributes an extensive range of analogue and digital imaging systems and IT solutions, mainly

Notice on Convocation of Extraordinary General Meeting of Shareholders of AB Klaipedos nafta20.11.2019 15:02:00 CETPress release

Notice is hereby given that on the initiative and by the resolution of the Board of AB Klaipedos Nafta, legal entity code 110648893, with the registered office at Burių str. 19, Klaipeda (hereinafter - the Company), Extraordinary General Meeting of Shareholders of the Company will be held on 12 December 2019 at 1:00 p.m. The meeting will be held in the Company’s office at Buriu str. 19, Klaipeda, in the administrative office of the Company (in the hall of the meeting on the 2nd floor). Agenda of the meeting: Regarding the approval of the additional decision of the Board of AB Klaipėdos nafta to pledge from 2025 all current and future amounts receivable (the Security Component) of the Company for the benefit of the Ministry of Finance of the Republic of Lithuania for the state guarantee granted by the Republic of Lithuania; Regarding the approval of the additional decision of the Board of AB Klaipėdos nafta to obtain and present up to EUR 20,000,000 (twenty million euros) annual bank gu

 Åland Index Solutions - a game changer tackling climate crisis at every transaction20.11.2019 14:10:00 CETPress release

Ålandsbanken Abp Pressrelease 20.11.2019 Åland Index Solutions - a game changer tackling climate crisis at every transaction Åland Index Solutions, a joint venture between Doconomy and Ålandsbanken, enables banks, payment providers and financial institutions to offer all customers transaction based impact calculations. Åland Index is the global index solution for CO2 emission calculations that guide consumers in their everyday consumption towards more sustainable choices. “With Åland Index Solutions we can engage all financial players in the fight against climate change. This collaboration is a milestone in creating a global standard for measuring the impact of consumption and totally changing the way we consume through connecting spending patterns with climate impact, says Nathalie Green CEO at Doconomy” The original Åland Index was developed in 2016 and the team has ever since been working to help consumers become aware of their impact on the planet. Åland Index is continuously being